Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Boso, M ^b   Cipriani, Andrea ^a   Barbui, C ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

AGRANULOCYTOSIS; BLOOD DYSCRASIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; RANDOMIZATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 44949139756     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006324     Document Type: Review

References (22)

1. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. British Medical Journal 1996;313:1200.
2. Bland 1997 Bland JM. Statistics notes. Trials randomised in clusters. British Medical Journal 1997;315:600.
3. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
4. Chakos 2001 Chakos M, Lieberman J, Hoffman E. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. American Journal of Psychiatry 2001;158:518-26.
5. Conley 2001 Conley RR, Kelly DL. Management of treatment-resistant schizophrenia. Biological Psychiatry 2001;50:898-911.
6. Correll 2003 Correll CU, Kissling W, Rummel C, Leucht S. Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 4.Art. No.: CD004579. DOI: 10.1002/14651858.CD004579.
7. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
8. Duggan 2005 Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2.Art. No.: CD001359. DOI: 10.1002/14651858.CD001359. pub2.
9. Egger 1997 Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;13:629-34.
10. Furukawa 2006 Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7- 10.
11. Gulliford 1999 Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83 876-83.
12. Hennen 2005 Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Research 2005;73:139-45.
13. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Cochrane Database of Systematic Reviews 2005, Issue 3.
14. Kane 1988 Kane J, Honigfeld G, Singer J. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-96.
15. Kontaxakis 2005 Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. European Psychiatry 2005;20 (5-6):409-15.
16. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
17. Mouaffak 2006 Mouaffak F, Tranulis C, Gourevitch R. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clinical Neuropharmacology 2006;29:28-33.
18. Remington 2005 Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19(10):843-72.
19. Rosenheck 1997 Rosenheck R, Cramer J, Xu W, Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 1997;337:809-15.
20. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of American Medical Association 1995;273:408-12.
21. Sernyak 2004 Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry 2004;65:1597-600.
22. Wahlbeck 1999 Wahlbeck K, Cheine MV, Essali A. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 4.Art. No.: CD000059. DOI: 10.1002/14651858.CD000059.